###### CURRICULUM VITAE

**Richard Charles Wilson Martin**

#### GOALS

* To be a dedicated Surgeon providing General Surgical care whilst specialising in Head/Neck and Cutaneous Surgical Oncology.
* To supply the highest levels of specialist care in a team environment whilst continuing to improve my skills and knowledge via research and development in the surgical field.
* To provide inspiration, leadership and encouragement to future generations of surgeons researchers and medical students.
* To foster collaboration with national and international centres to improve patient care and research.

#### EDUCATION

1992 - 1994 Christchurch School of Medicine, University of Otago

1990 - 1991 University of Otago (Knox College 1990)

1989 - University of Canterbury

1984 - 1988 Christ's College (Prefect, Deputy head of house, Captain of athletics, 1st XV

 rugby)

#### QUALIFICATIONS

Master of Surgery (University of Sydney) 2007

FRACS December 2004

FRACS Part II October 2002

FRACS Part I - MCQ October 1996, OSCA July 1998

MBChB 1994 (University of Otago) Registration No. 20448

**EMPLOYMENT**

**Current Cutaneous Surgical Oncologist, Head/Neck, and General Surgeon**

 **Waitemata District Health Board, North Shore Hospital, Auckland**

 **(Commencement date 2/7/07)**

 **Senior Lecturer University of Auckland**

 **New Zealand Melanoma Unit/Waitemata Specialist Centre**

2007Surgical Oncologist, Sydney Melanoma Unit

 Visiting General Surgeon, Royal Prince Alfred Hospital

 Lecturer, University of Sydney, Department of Surgery

 Private Practice, Mater Hospital, Sydney Day Surgery

1. Surgical Oncology Fellowship, Royal Prince Alfred:

Sydney Head and Neck Cancer Institute (Professor C O’Brien)

Locum General Surgery Consultant (Albury, Taree)

1. Surgical Oncology Fellowship, Royal Prince Alfred:

 Sydney Melanoma Unit (Professor J Thompson)

1. Advanced Training (Year 5) North shore Hospital:

 General/Endocrine/Head & Neck/Melanoma/Breast (Harman/Juhasz)

 Auckland Hospital: Head & Neck Fellowship (McIvor/Chaplin/Morton)

2003 Advanced Training (Year 4)

 Middlemore Hospital:

General/Vascular (Officer/Vann)

Auckland Hospital:

General/Endocrine/Head & Neck/Melanoma/Breast (Shaw/Jones/Ng)

1. Advanced Training (Year 3) Auckland Hospital:

 General/Vascular (Civil/MacCormick)

 General/Colorectal (Bisset/Parry)

1. Advanced Training (Year 2) Waikato Hospital:

 General/Upper GI (Schroeder/Grunewald)

 General/Colorectal (Kato/Van Dalen)

1. Advanced Training (Year 1) Tauranga Hospital:

 General/Vascular (Breeze/Partridge)

 General/Breast (Cable/Kumar)

1999-1998 Basic Surgical Training

 North Shore Hospital: General Surgical Registrar (Theobald/Harman)

 Auckland Healthcare: Urology Registrar (Bolton/Rothwell)

 Middlemore Hospital:

 General Surgical Registrar (Farmilo/Connolly)

 Plastic Surgical Registrar (Mellow/de Chalain)

* 1. Resident Medical Officer positions in Auckland and the UK

# INTERESTS

 Rugby Union Travel

 Les Mills Theatre

Skiing Egyptian antiquity

 Formula One Art History

 Touch Rugby Reading

**TEACHING EXPERIENCE**

* Organiser of RACS Part II exam, May 2008, Auckland
* Auckland Advanced Trainee Teaching Program 2007-2021
* NSW Advanced Training Teaching Program 2005-2006
* Student tutorials (University of Sydney Medical School) 2005-2007
* GP Training Program 2003-2004, 2008 to 2021
* Basic Surgical Skills for Junior Medical Staff (Clinical skills training centre –Greenlane Hospital) 2003-2004
* General History and Examination methods for Clinical Methods Students (Auckland Medical School) 2002-2004, 2007-2021

#### COURSES/CONFERENCES

* Virtual ASC, Wellington, May 2021
* 8th Multidisciplinary Update on Thyroid and Parathyroid Surgery, Noosa, November 2019
* World Congress of Dermatology, Milan, June 2019
* Melnet Summit, Auckland, 2018
* SCCA meeting, Broadbeach, May 2018
* NZAGS, Paihia, March 2018
* World Melanoma Congress, Brisbane, October 2017
* Queenstown Research Week-Melanoma, Queenstown, August 2017
* Locoregional melanoma conference, Peter Macallum Cancer Centre, Melbourne 2016
* ISNS, Milan, May 2016
* Melnet Summit, Auckland 2015
* NZAGS, Queenstown 2015
* ASCO, Chicago 2014
* Global controversies in skin cancer, Brisbane 2013
* ISNS Meeting, San Francisco, May 2013
* The European Multidisciplinary Cancer Congress, Stockholm, September 2011

##### ASCO, Chicago 2011

* + Dermoscopy course, MELNET, Wellington 2011

##### SMR 4th Melanoma and Skin Cancers Meeting, Sydney, November 2010

* + European Association of Dermato-Oncology, Athens, June 2010
	+ NZAGS, Queenstown 2010
	+ Melanoma Summit, NZ 2009, 2011, 2013

##### Advanced Cardiac Life Support, 2009

* + World Melanoma Congress, Vienna, May 2009
	+ AHNS meeting, San Francisco, July 2008
	+ World Sentinel Node Conference, Sydney, February 2008
	+ ASC 1999-2006, 2009, 2012, 2013
	+ ANZHNS Conference, 2006, Wellington
	+ World Melanoma Congress 2005, Vancouver, Canada
	+ ANZHNS Conference 2005, Sydney
	+ ASM (NZ) 2000-2004
	+ NZAGS meetings 2000-4. 2010, 2011, 2012, 2015
	+ EMST Refresher Course October 2004
	+ Head and Neck U/S Course, May 2004
	+ Tyco Laparoscopic Training Days 2002-2004
	+ Laparoscopic Ventral Hernia Repair Course, October 2003
	+ DSTC, August 2003
	+ Trauma Training Days, 1998-2003

### FAST/AAA Course, November 2001

* + CLEAR Workshop, February 2000
	+ EMST Course-Auckland Hospital, March 1998
	+ BasicLaparoscopy Course-Surgical Skills Training Unit, Greenlane Hospital, January 1998

# MEMBERSHIPS

* Faculty member of World Melanoma Congress
* Chairman of the New Zealand Melanoma Stream Working Group
* Melanoma Network of New Zealand, MELNET (Executive committee member)
* Melanoma New Zealand (Board member)
* International Sentinel Node Society (Executive Committee member)
* Melanoma and Skin Cancer Trials group (MASC), Executive committee member)
* Journal reviewer (Melanoma Research, Head and Neck, British Medical Journal, Annals of Surgery, Annals of Surgical Oncology, ANZJS)
* New Zealand Association of General Surgeons
* Australian and New Zealand Head and Neck Cancer Society
* Head and Neck Section of RACS
* Surgical Oncology Section of RACS
* McLaren Mercedes F1 Team
* Tautai (Pacific arts group)

# PUBLICATIONS

1. Proposed quality performance indicators of sentinel lymph node biopsy for cutaneous melanoma. Accepted for publication in ANZJS, April 2021
2. A case of cystic lymphatic malformation mimicking acute appendicitis in an adult patient: a rare diagnostic pitfall. M Joret, A Nananyakkra, RCW Martin. BMJ Case Rep 2021;14:e239509
3. Radiological Imaging of Melanoma: A Review to guide clinical practice in New Zealand. NZMJ 2021; 134(1528): 79-87
4. Distinctive populations of human lymph node stromal cells contribute to cancer-associated fibroblasts following melanoma metastasis (Running title: Stromal cells in melanoma-infiltrated lymph nodes). Jennifer Eom,Saem Mul Park,Vaughan Feisst,Chun-Jen J. Chen,Julie D. McIntosh, Catherine E. Angel,Adam Bartlett, Richard Martin,Jonathan Cebon,Michael A Black, Anna E.S. Brooks,P. Rod Dunbar. Cancer Immunology Research 2020; 8(8): 990-1003
5. Quality Measures in Cervical Lymphadenectomy for cutaneous malignancy by Head and Neck trained General Surgeons. F Nahab, Sita Olek, RCW Martin. NZMJ 2020; 133(1520); 50-60
6. E-referrals and teledermatoscopy grading for melanoma, a successful model of care. AJD 2020 May; 61(2): 147-151
7. Quality assessment of a large primary skin cancer service in Auckland, New Zealand. NZMJ 2020; 133(1509):17-27
8. Sentinel Node Biopsy in 105 high risk cutaneous SCC of the Head and Neck: Results of a multicentre trial. Craig P. Mooney, Richard C. W. Martin, Richard Dirven, Bruce G. Ashford, Kerwin Shannon, Carsten E. Palme, Quan Ngo, James Wykes, Sarah Davies, Kan Gao, Sydney Ch’ng, Tsu-Hui (Hubert) Low, Ruta Gupta, Jonathan R. Clark. Ann Surg Oncol 2019 Dec; 26(13):4481-4488.
9. Body site distribution of squamous cell and basal cell cancer in a high risk New Zealand population. Essa Tawfiq, Mark Elwood, G Rolfe, P Emanual, Richard Martin. Journal of Experimental Dermatology 2019; 6(2): 030
10. WOUND Study: a cost-utility analysis of negative pressure wound therapy following split-skin grafting for lower limb skin cancer. Helen J Ker, Abbas Al-Murrani, Gill Rolfe, Richard CW Martin. Journal of Surgical Research 2019; 253: 308-314
11. Elective Services Productivity and Effectiveness Review: Waitemata DHB Skin Clinic and Procedure Model of Care. February 2018 EPUB. M Broome, K Macfarlane, RCW Martin
12. WOUND trial. A prospective randomised trial of bolster dressing v’s negative pressure suction dressing and early mobilisation for lower limb skin grafts.

R Vather, H Hammodat, K Gale, RCW Martin. JPRAS 2018; 71(7): 1100-1102

1. The burden of non-melanoma skin cancer in Auckland, NZ. A Podicherry, P Emanual, I Meredith, RCW Martin, M Elwood. Australasian Journal of Dermatology 2018; 59 (3): 210-213
2. Epidemiology of Melanoma in Situ in New Zealand. Sam Rice, Richard Martin. NZMJ 2018; 131(1482): 73-79
3. Establishment of a national “complex” BCC database. M Carpenter, RCW

Martin. RCW Martin, M Carpenter, G Rolfe, R Carpenter. Clinical Skin. Cancer 2016; [1(2](https://www.sciencedirect.com/science/journal/24058645/1/2)): 82-87

1. Prospective study of sentinel node biopsy for high risk cutaneous squamous cell carcinoma of the head and neck. Sinclair M. Gore, Douglas Shaw, Richard C.W. Martin, Kathryn Roth, Roger Uren, Kan Gao, Sarah Davies, Bruce G. Ashford, Quan Ngo, Kerwin Shannon and Jonathan R. Clark. Head & Neck April 2016; 38: 884–889
2. Successful melanoma triage by virtual lesion clinic (teledermatology). Congalton AT, Oakley AM, Rademaker M, Bramley D, Martin RCW. JEADV 2015 Dec; 29(12): 2423-8
3. Predicting lymph node metastases in cutaneous squamous cell carcinoma: use of a morphological scoring system. Nicholas J M Agar, Christopher Kirton, Rajan Patel, Richard C W Martin, Neville Angelo, Patrick O Emanuel. NZMJ 2015; 128(1411)
4. Epidemiology of Merkel Cell Carcinoma in New Zealand: A population based study. Robertson JP, Liang ES, Martin RC. B J of Dermatology 2015; 173(3):835–837
5. Standards of Service Provision for Melanoma Patients in New Zealand. RCW Martin, Chairman of Melanoma group, published 2013.
6. Combined cellular blue naevus and trichoepithelioma. Martin RC, Emanuel PO. J Clin Aesthet Dermatol. 2013 Aug; 6(8):35-8.
7. The Management of Cervical Nodes in Cutaneous Melanoma. RCW Martin, K Gao, K Shannon, A Spillane, J Stretch, CJ O’Brien, JF Thompson. Ann Surg Oncol 2012 Nov; 19(12): 3926-32.
8. Malignant Melanoma amongst Maori and New Zealand Europeans, 2000-2004.T Hore, E Robinson, RCW Martin. WJS 2010; 34(8): 178801792
9. Cutaneous Melanoma in New Zealand: 2000-2004. Jennifer JC Liang, Elizabeth Robinson and Richard CW Martin. ANZJS 2010; 80(5): 321-316.
10. So-called “malignant blue naevus” – a clinico-pathological study of 23 cases. Richard C. W. Martin, Rajmohan Murali, Richard A. Scolyer, Patrick, Fitzgerald, Margaret H. Coleman and John F. Thompson. Cancer 2009; 115(13): 2949-2955.
11. Efficacy of repeat Positron Emission Tomography (PET) in the evaluation of patients treated with chemoradiotherapy for mucosal head and neck cancer. RCW Martin, M Fulham, CJ O’Brien et al. Head Neck. 2009; 31(2): 244-50.

# Adjuvant Postoperative Radiotherapy to Cervical Lymph Nodes in Cutaneous Melanoma: Is there Any Benefit for High Risk Patients? Marc D Montcrief, Richard Martin, Christopher J. O’Brien, Kerwin F Shannon, Jonathon R Clark, Kan Gao, William M McCarthy and John F Thompson. Annals of Surgical Oncology 2008; 15(11): 3022-3027.

1. Uteroplacental ischemia results in proteinuric hypertension and elevated sFLT-1. A Makris, C Thornton, S Thompson, J Thompson, R Martin, P Mckenzie, R Ogle, R Waugh, A Hennessy. Kidney International 2007; 71(10): 977-84.
2. The role of Sentinel Node Biopsy in high risk Cutaneous Squamous Cell Carcinoma. R Martin. Master’s thesis, University of Sydney, 2007
3. Ossified adrenocortical adenoma: an unusual radiological and morphological appearance. EDM Fong, R Martin, IM Cranshaw, A Morrine, JHF Shaw. ANZJS 2005; 75(9): 835
4. Necrotising Fasciitis in South Auckland. A Tiu, RCW Martin, A MacCormick, A Hill.

 ANZJS 2005; 75(1-2): 32-4

1. Allergic reactions to enoxaparin and heparin: a case report and review of the literature. Albert Tiu, Jia-Min Pang, Richard Martin, Neil Officer. NZMJ 2004; 117-120
2. Cutaneous Melanoma in Caucasian New Zealanders. RCW Martin, E Robinson. ANZJS 2004; 74: 233-7
3. Sentinel node biopsy in breast cancer: validation study and comparison of blue dye alone with triple modality localization. RCW Martin, W Myer-Rochow, CR Harman. ANZJS 2003; 73(10): 815-818

# BOOK CHAPTERS

1. Non-melanoma skin cancer. RCW Martin, W Cooper, CS Lee, CJ O’Brien. Head and Neck Surgery and Oncology: Principles and Practice. 2006 BC Decker online textbook. [www.bcdecker.com](file:///E%3A%5Cwww.bcdecker.com)
2. Stell and Maran’s Text Book of Head and Neck Surgery and Oncology, 5th Edition, 2012. Hodder and Arnold. Chapter 36. Non melanoma and melanoma skin cancer. RCW Martin, J Clark.
3. Treating advanced Basal Cell Carcinoma in NZ. Research review educational series, 2014. [www.researchreview.co.nz](http://www.researchreview.co.nz)

# CURRENT RESEARCH

# MelMart II, margins assessment for melanoma. New Zealand Primary Investigator. R Martin

# The cost of managing skin cancer in New Zealand, a burgeoning problem.

R Martin, M Elwood, R Ogilvie

* + Self-assessed sunbed use is not associated with melanoma diagnosis in patients attending a teledermatoscopy clinic in New Zealand Deborah Lambie, A Oakley, R Martin.

# Blood Biomarkers Study, C Print, R Stephens, J Mathy, R Martin.

# Immune response in metastatic melanoma. University of Auckland. R Dunbar, R Martin, J Mathy.

* Lymphadenectomy database at WDHB-Quality Analysis of groin, axilla and neck lymphadenectomies. F Nahab, Sita Olek, RCW Martin.

# Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/KEYNOTE-054). Co-investigator

* RADICAL trial, ANZMTG. Imiquimod v’s Radiotherapy for inoperable melanoma in situ. Primary Investigator, NZ.
* COMBI-AD adjuvant treatment study in resected Stage III melanoma. GSK sponsored trial. Co-investigator.
* Establishment of a thyroid database at WDHB
* Metastatic cutaneous SCC in Auckland. R Martin, P Emanual, I Cranshaw, J Keneilly
* Cost of non-melanoma skin cancer in Auckland, NZ. R Martin, P Emanual, I Cranshaw, J Keneilly, M Elwood
* Molecular analysis of high risk cutaneous SCC and predictors of lymph node metastases. R Martin, D Hoon, Pat Emanuel.

**CLINICAL TRIALS**

* + MelMart II
	+ MK3475-913. Anti – PD 1 in Stage 4 MCC
	+ NSC3 Biomarker study
	+ RADICAL trial
	+ MK-3475-054/KEYNOTE-054
	+ COMBI-AD, GSK
	+ Vismodegib, open label phase II trial for BCC. STEVIE Trial
	+ MSLT-2
	+ BRIM-3
	+ ANZMTG/TROG Adjuvant radiotherapy trial for resected Stage IIIB/C melanoma
	+ DERMA. Co-Investigator “MAGE-3 vaccine trial” sponsored by GSK.
	+ ECOG1697
	+ POST trial

# PRESENTATIONS

* Melnet Webinar: Multi-disciplinary management of complex stage III and IV melanoma of the head and neck. 4th November 2020.
* Teledermatology and e-referral grading for melanoma, a successful model of care. World Congress of Dermatology, Milan, May 2019
* The use of sentinel node biopsy and novel molecular approaches to improve triage in high risk cutaneous SCC of the head and neck. World Congress of Dermatology, Milan, May 2019
* WDHB Skin Service: GP Surgeon Scheme: an effective model of care. University of Auckland/WDHB Research Symposium 2019
* Teledermatology and e-referral grading for melanoma, a successful model of care. MELNET Summit, November 2018
* WDHB Skin Service: GP Surgeon Scheme: an effective model of care. MELNET Summit, November 2018
* Melanoma Standards Update. MELNET Summit, November 2018
* The virtual skin lesion clinic (VLC) – an evaluation of a new triage system for melanoma. MELNET Summit, November 2018
* Sentinel Lymph Node Biopsy in high risk Cutaneous SCC of the Head and Neck. MELNET Summit, November 2018
* Sentinel Lymph Node Biopsy in high risk Cutaneous SCC of the Head and Neck. ISNS meeting Tokyo, October 2018
* Melanoma Standards Update. SCCA plenary session, Broadbeach, May 2018
* E referrals and teledermatology: a successful model of care. SCCA conference, Broadbeach, May 2018
* Auditing Care of Thyroid and Parathyroid patients at North Shore Hospital Surgical Endocrine Unit. Poster by H Royal RACS (Sydney) May 2018.
* Melanoma surgery in the era of immune and targeted therapy. Best practice 2018.NZAGS conference, Paihia, March 2018
* E referrals and teledermatology: a successful model of care. World Melanoma

Congress, Brisbane, October 2017

* Axillary node dissection: Key performance indicators and quality assurance

Poster at World Melanoma Congress, Brisbane 2017

* Staging of non-melanoma skin cancer-a Surgical Oncologists perspective. Royal Australasian College of Pathologists Conference, Rotorua, September 2017
* Surgery in the era of immunotherapy and targeted therapy. NZGP conference 2017, Rotorua, June 2017
* Total Lymph Node Yield as a marker of quality assurance in axillary

Lymphadenectomy for metastatic melanoma. Poster ASC, Adelaide, May 2017

* The burden of non-melanoma skin cancer in Auckland, NZ. A Podicherry, RCW Martin. IFHNOS meeting, October 2016
* Sentinel Lymph Node Biopsy in Cutaneous Head and Neck Malignancies
IFHNOS meeting, Auckland, October 2016
* RADICAL trial, RANZCR meeting, Wellington, August 2016
* Complex BCC definition and database, RANZCR meeting, Wellington, August 2016
* Surgical management of metastatic melanoma. NZGP conference, June 2016
* Sentinel node biopsy in high risk cutaneous SCC. ISNS Plenary session, Milan, May 2016
* Isolated limb infusion. Australasian Plastic and Reconstructive trainee’s conference, Auckland, March 2016
* Epidemiology of non-melanoma skin cancer in Auckland, NZ. A Podicherry, RCW Martin. Global controversies in skin cancer, Brisbane 2015
* Standards of service provision for melanoma patients in New Zealand. Presented at Melanoma Summit, 2015.
* Epidemiology of Melanoma in NZ, 2009-2013. Poster at NZAGS meeting, 2015 K Broughton, R Martin.
* Sentinel node biopsy for high risk head and neck cutaneous squamous cell carcinoma. Global controversies in skin cancer, Brisbane 2013
* Epidemiology of Melanoma in situ in New Zealand. S Rice, RCW Martin. Global controversies in skin cancer, Brisbane 2013
* Targeted therapies in skin cancer-the evidence. Invited speaker for Head and Neck section of ASC, Auckland 2013
* Thyroidectomy in the morbidly obese, no time to defer. Invited speak for

Surgical Oncology section of ASC, Auckland 2013

* Metastatic Risk in cutaneous Squamous Cell Carcinoma (cSCC).Chris Kirton, R Martin, Raj Patel, Pat Emanuel. ASC, Auckland 2013
* The role of Sentinel Node Biopsy in Rare Cutaneous Malignancies

Kath Gale, RCW Martin

ASC, Kuala Lumpur, May 2012

* Epidemiology of Thyroid cancer in NZ, 2000-2004

Kath Gale, RCW Martin NZAGS meeting, Nelson, March 2012

* Melanoma Update. RACS training day. Nelson 2010
* SNIC Trial. Sentinel node biopsy in high risk non-melanoma skin cancer.

RCW Martin. EADO, Athens, June 2010

* SNIC Trial. Sentinel node biopsy in high risk non-melanoma skin cancer

RCW Martin. NZAGS, Tauranga, March 2010

* Sentinel Node Biopsy for Cutaneous Melanoma, an update.

RCW Martin. NZAGS, Tauranga, March 2010

* NZ leads the world in Melanoma incidence rates.

RCW Martin, J Liang, E Robinson

World Melanoma Conference, Vienna, May 2009

* The Management of Cervical Lymph Nodes in Cutaneous Melanoma. RCW Martin, JF Thompson, CJ O’Brien.

ASC, Sydney, May 2006 and World Melanoma Conference, Vienna, May 2009

* The prognostic significance of sentinel node status in the neck compared with other node fields. RCW Martin, JF Thompson, R Uren, CJ O’Brien.

Head and Neck 2005, Sydney, November 2005

* The role of PET in assessing treatment response in the nonsurgical management of mucosal Squamous Cell Carcinoma of the Head and Neck.

Head and Neck 2005, Sydney, November 2005

* So-called Malignant Blue Naevus has a similar prognosis to other subtypes of Melanoma.

RCW Martin, JF Thompson, RS Scolyer.

Poster (SO029P) at ASC, Sydney, May 2006

*ANZJS* 2006; 76 (Suppl.1)

* Poster at World Melanoma Conference, Vancouver, September 2005
* The prognostic significance of sentinel node status in the neck compared with other node fields. RCW Martin, JF Thompson, R Uren, CJ O’Brien.

Poster (SO027P) at ASC, Sydney, May 2006

*ANZJS* 2006; 76 (Suppl.1)

Poster at World Melanoma Conference, Vancouver, September 2005

* New Zealand Parotid pathology differs from the rest of the world.

 RCW Martin and JHF Shaw (presenter)

 ASC (Head & Neck Section) Brisbane, May 2003

 *ANZJS* 2003; 73 (Suppl.)

* Cutaneous Melanoma in Caucasian New Zealanders.

 RCW Martin, E Robinson

 ASM Christchurch, September 2002

* Sentinel Node Biopsy: Triple modality versus Patent Blue Dye, A validation

 Study. RCW Martin, CR Harman

Poster (Presentation) ASC (Breast Section) Melbourne, May 2000

* A Clinical Review of the Multicultural South Auckland Breast Clinic.

 RCW Martin, JP Collins, GP Poole.

 Poster and Presentation ASC (Breast Section) Auckland, May 1999